- Home
- ORIO vs IGC Comparison
ORIO vs IGC Comparison
Compare ORIO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIO | IGC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | Canada | United States |
| Employees | 178 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 25.0M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | ORIO | IGC |
|---|---|---|
| Price | $0.96 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 47.2K | ★ 255.9K |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | $78.15 | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.24 |
| 52 Week High | $1.40 | $0.50 |
Technical Indicators
Market Signals| Indicator | ORIO | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 47.79 |
| Support Level | N/A | $0.25 |
| Resistance Level | $1.27 | $0.31 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 18.92 | 36.20 |
Price Performance
Historical ComparisonAbout ORIO Orion Digital Corp. Common Shares
Orion Digital Corp is a digital finance company operating across wealth, payments, and digital assets. Through its Investing wealth platform, Carta World-wide payments infrastructure, and long-duration Bitcoin treasury plan - combined with a disciplined, multi-engine compounding model. Orion Digital is focused on compounding value through execution, scale, and capital discipline.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.